Get started
Author

Dorothea Schipp

Observed names: D. Schipp, Schipp, Dorothea
ORCID: 0000-0002-4860-786X
Observed ORCID: 0000-0002-4860-786X
OpenAlex ID: A5084566363
Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study
2023 · Andreas Tiede, Christina Hart, et al. · The Lancet Haematology · 85
Biomarker monitoring of controlled dietary acrylamide exposure indicates consistent human endogenous background
2017 · Katharina Goempel, Laura Tedsen, et al. · Archives of Toxicology · 57
PDF
Consumption of a dark roast coffee decreases the level of spontaneous DNA strand breaks: a randomized controlled trial
2014 · T. Bakuradze, R. Lang, et al. · European Journal of Nutrition · 57
Four-week coffee consumption affects energy intake, satiety regulation, body fat, and protects DNA integrity
2014 · Tamara Bakuradze, Gina Alejandra Montoya Parra, et al. · Food Research International · 55
Emicizumab versus immunosuppressive therapy for the management of acquired hemophilia A
2024 · Christina Hart, Robert Klamroth, et al. · Journal of Thrombosis and Haemostasis · 38
Absorption of Anthocyanin Rutinosides after Consumption of a Blackcurrant ( Ribes nigrum L.) Extract
2019 · Teresa Röhrig, Verena Kirsch, et al. · Journal of Agricultural and Food Chemistry · 36
PDF
Coffee consumption rapidly reduces background DNA strand breaks in healthy humans: Results of a short‐term repeated uptake intervention study
2015 · Tamara Bakuradze, Roman Lang, et al. · Molecular Nutrition & Food Research · 27
Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers
2021 · Frank Pistrosch, Jan B. Matschke, et al. · Diabetologia · 24
PDF
Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial
2023 · A. S. Kubasch, P. Peterlin, et al. · Leukemia · 19
PDF
Dark coffee consumption protects human blood cells from spontaneous DNA damage
2019 · Gudrun Pahlke, Eva Attakpah, et al. · Journal of Functional Foods · 13
A 4-week consumption of medium roast and dark roast coffees affects parameters of energy status in healthy subjects
2014 · Annett Riedel, Natalie Dieminger, et al. · Food Research International · 12
Consumption of a dark roast coffee blend reduces DNA damage in humans: results from a 4-week randomised controlled study
2018 · Dorothea Schipp, Jana Tulinska, et al. · European Journal of Nutrition · 11
Daily consumption of a dark-roast coffee for eight weeks improved plasma oxidized LDL and alpha-tocopherol status: A randomized, controlled human intervention study
2019 · Christina M. Hochkogler, Kerstin Schweiger, et al. · Journal of Functional Foods · 10
Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms – results of the EUROPE trial by EMSCO
2022 · Anne Sophie Kubasch, Aristoteles Giagounidis, et al. · Leukemia · 9
PDF
Modulation of inflammatory gene transcription after long-term coffee consumption
2014 · Swantje Winkler, Natalie Dieminger, et al. · Food Research International · 6
Efficacy and Safety of Bemcentinib in Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Failing Hypomethylating Agents
2020 · Anne Sophie Kubasch, Pierre Peterlin, et al. · Blood · 4
Preliminary Safety and Efficacy of Luspatercept Initiated at Maximum Approved Dose in Patients with Transfusion Dependent Anemia Due to Very Low, Low and Intermediate Risk MDS with Ring Sideroblasts: First Results of the Lusplus Trial
2024 · Katharina S. S. Götze, Anna Hecht, et al. · Blood · 2
PDF
1525P Nab-paclitaxel/gemcitabine with or without epigenetic targeting followed by consolidating immune targeting with durvalumab and lenalidomide in patients with advanced pancreatic ductal adenocarcinoma: Results from the SEPION/AIO-PAK-0118 phase I/II study
2024 · J.T. Siveke, M. Sinn, et al. · Annals of Oncology · 2
PDF
Abstract CT195: Interim safety results from SEPION/AIO-PAK-0118: A multicenter, Phase I/II study of sequential epigenetic and immune targeting in combination with nab-paclitaxel/gemcitabine in patients with advanced pancreatic ductal adenocarcinoma
2023 · Jens T. Siveke, Marianne Sinn, et al. · Cancer Research · 1
Emicizumab Versus Immunosuppression for Acquired Hemophilia Α (AHA)
2023 · Christina Hart, Robert Klamroth, et al. · Blood
LB 01.2 Emicizumab Prophylaxis Instead of Immunosuppressive Therapy in Patients with Acquired Hemophilia A (AHA)
2023 · A. Tiede, C. Hart, et al. · Research and Practice in Thrombosis and Haemostasis
S169: Clinical and Molecular Markers for Predicting Response to Romiplostim Treatment in Lower-risk Myelodysplastic Syndromes
2022 · A. S. Kubasch, A. Giagounidis, et al. · HemaSphere
A Molecular-Based Response Prediction Model to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome and Severe Thrombocytopenia
2020 · Anne Sophie Kubasch, Aristoteles Giagounidis, et al. · Blood
Corrigendum to “Dark coffee consumption protects human blood cells from spontaneous DNA damage” [J. Funct. Foods 55 (2019) 285–295]
2020 · Gudrun Pahlke, Eva Attakpah, et al. · Journal of Functional Foods
PDF
Abstract LB-249: Coffee drinking decreases background DNA strand breaks in humans: A randomized controlled trial
2014 · Gerhard Eisenbrand, Tamara Bakuradze, et al. · Cancer Research
Works count: 27
Citation count: 468
H-index: 11
I10-index: 13
Year
Topic
Type